Tamoxifen resistance in breast cancer

Valerie J. Wiebe, C. Kent Osborne, Suzanne A W Fuqua, Michael W. DeGregorio

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Tamoxifen (TAM) resistance is the underlying cause of treatment failure in many breast cancer patients receiving TAM. The mechanism(s) involved in TAM resistance are poorly understood. A variety of mechanisms have been proposed but only limited evidence exists to substantiate them. Studies have now shown that in many patients TAM resistance is not related to the down regulation or loss of estrogen receptors (ER). Variant ER have been identified, but their significance clinically remains to be proven. Since breast cancer cells secrete several estrogen-regulated growth factors and growth inhibitors that may have autocrine or paracrine activity, altered growth factor production is another possible mechanism for TAM resistance. Tissue-specific transcription activating factors that may alter how the signal induced by TAM binding to the receptor is interpreted by the cell also require further investigation. An increase in antiestrogen binding sites (AEBS), which could effectively partition TAM and reduce its concentration at the ER has also been proposed as a potential mechalism. Pharmacologic mechanisms, such as a shift in metabolism toward the accumulation of estrogenic metabolites, are supported by recent data demonstrating metabolite E and bisphenol in tumors from TAM-resistant patients. Furthermore, a decrease in tumor TAM accumulation and an altered metabolite profile have been reported in TAM-resistant breast tumors grown in nude mice. These and other studies suggest that TAM resistance may be multifactorial in nature, but definitive identification of mechanisms that are operative in clinical TAM resistance requires further study.

Original languageEnglish (US)
Pages (from-to)173-188
Number of pages16
JournalCritical Reviews in Oncology and Hematology
Volume14
Issue number3
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Tamoxifen
Breast Neoplasms
Estrogen Receptors
Intercellular Signaling Peptides and Proteins
Activating Transcription Factors
Growth Inhibitors
Estrogen Receptor Modulators
Treatment Failure
Nude Mice
Neoplasms
Estrogens
Down-Regulation
Binding Sites

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Wiebe, V. J., Osborne, C. K., Fuqua, S. A. W., & DeGregorio, M. W. (1993). Tamoxifen resistance in breast cancer. Critical Reviews in Oncology and Hematology, 14(3), 173-188. https://doi.org/10.1016/1040-8428(93)90008-R

Tamoxifen resistance in breast cancer. / Wiebe, Valerie J.; Osborne, C. Kent; Fuqua, Suzanne A W; DeGregorio, Michael W.

In: Critical Reviews in Oncology and Hematology, Vol. 14, No. 3, 1993, p. 173-188.

Research output: Contribution to journalArticle

Wiebe, VJ, Osborne, CK, Fuqua, SAW & DeGregorio, MW 1993, 'Tamoxifen resistance in breast cancer', Critical Reviews in Oncology and Hematology, vol. 14, no. 3, pp. 173-188. https://doi.org/10.1016/1040-8428(93)90008-R
Wiebe, Valerie J. ; Osborne, C. Kent ; Fuqua, Suzanne A W ; DeGregorio, Michael W. / Tamoxifen resistance in breast cancer. In: Critical Reviews in Oncology and Hematology. 1993 ; Vol. 14, No. 3. pp. 173-188.
@article{1f0e866b6d5048798b35f4da739b1d74,
title = "Tamoxifen resistance in breast cancer",
abstract = "Tamoxifen (TAM) resistance is the underlying cause of treatment failure in many breast cancer patients receiving TAM. The mechanism(s) involved in TAM resistance are poorly understood. A variety of mechanisms have been proposed but only limited evidence exists to substantiate them. Studies have now shown that in many patients TAM resistance is not related to the down regulation or loss of estrogen receptors (ER). Variant ER have been identified, but their significance clinically remains to be proven. Since breast cancer cells secrete several estrogen-regulated growth factors and growth inhibitors that may have autocrine or paracrine activity, altered growth factor production is another possible mechanism for TAM resistance. Tissue-specific transcription activating factors that may alter how the signal induced by TAM binding to the receptor is interpreted by the cell also require further investigation. An increase in antiestrogen binding sites (AEBS), which could effectively partition TAM and reduce its concentration at the ER has also been proposed as a potential mechalism. Pharmacologic mechanisms, such as a shift in metabolism toward the accumulation of estrogenic metabolites, are supported by recent data demonstrating metabolite E and bisphenol in tumors from TAM-resistant patients. Furthermore, a decrease in tumor TAM accumulation and an altered metabolite profile have been reported in TAM-resistant breast tumors grown in nude mice. These and other studies suggest that TAM resistance may be multifactorial in nature, but definitive identification of mechanisms that are operative in clinical TAM resistance requires further study.",
author = "Wiebe, {Valerie J.} and Osborne, {C. Kent} and Fuqua, {Suzanne A W} and DeGregorio, {Michael W.}",
year = "1993",
doi = "10.1016/1040-8428(93)90008-R",
language = "English (US)",
volume = "14",
pages = "173--188",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Tamoxifen resistance in breast cancer

AU - Wiebe, Valerie J.

AU - Osborne, C. Kent

AU - Fuqua, Suzanne A W

AU - DeGregorio, Michael W.

PY - 1993

Y1 - 1993

N2 - Tamoxifen (TAM) resistance is the underlying cause of treatment failure in many breast cancer patients receiving TAM. The mechanism(s) involved in TAM resistance are poorly understood. A variety of mechanisms have been proposed but only limited evidence exists to substantiate them. Studies have now shown that in many patients TAM resistance is not related to the down regulation or loss of estrogen receptors (ER). Variant ER have been identified, but their significance clinically remains to be proven. Since breast cancer cells secrete several estrogen-regulated growth factors and growth inhibitors that may have autocrine or paracrine activity, altered growth factor production is another possible mechanism for TAM resistance. Tissue-specific transcription activating factors that may alter how the signal induced by TAM binding to the receptor is interpreted by the cell also require further investigation. An increase in antiestrogen binding sites (AEBS), which could effectively partition TAM and reduce its concentration at the ER has also been proposed as a potential mechalism. Pharmacologic mechanisms, such as a shift in metabolism toward the accumulation of estrogenic metabolites, are supported by recent data demonstrating metabolite E and bisphenol in tumors from TAM-resistant patients. Furthermore, a decrease in tumor TAM accumulation and an altered metabolite profile have been reported in TAM-resistant breast tumors grown in nude mice. These and other studies suggest that TAM resistance may be multifactorial in nature, but definitive identification of mechanisms that are operative in clinical TAM resistance requires further study.

AB - Tamoxifen (TAM) resistance is the underlying cause of treatment failure in many breast cancer patients receiving TAM. The mechanism(s) involved in TAM resistance are poorly understood. A variety of mechanisms have been proposed but only limited evidence exists to substantiate them. Studies have now shown that in many patients TAM resistance is not related to the down regulation or loss of estrogen receptors (ER). Variant ER have been identified, but their significance clinically remains to be proven. Since breast cancer cells secrete several estrogen-regulated growth factors and growth inhibitors that may have autocrine or paracrine activity, altered growth factor production is another possible mechanism for TAM resistance. Tissue-specific transcription activating factors that may alter how the signal induced by TAM binding to the receptor is interpreted by the cell also require further investigation. An increase in antiestrogen binding sites (AEBS), which could effectively partition TAM and reduce its concentration at the ER has also been proposed as a potential mechalism. Pharmacologic mechanisms, such as a shift in metabolism toward the accumulation of estrogenic metabolites, are supported by recent data demonstrating metabolite E and bisphenol in tumors from TAM-resistant patients. Furthermore, a decrease in tumor TAM accumulation and an altered metabolite profile have been reported in TAM-resistant breast tumors grown in nude mice. These and other studies suggest that TAM resistance may be multifactorial in nature, but definitive identification of mechanisms that are operative in clinical TAM resistance requires further study.

UR - http://www.scopus.com/inward/record.url?scp=0027177873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027177873&partnerID=8YFLogxK

U2 - 10.1016/1040-8428(93)90008-R

DO - 10.1016/1040-8428(93)90008-R

M3 - Article

C2 - 8397846

AN - SCOPUS:0027177873

VL - 14

SP - 173

EP - 188

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -